SCHEMBL6009312

SCHEMBL6009312

CCCCNC(=O)NSC

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 8/20 0.59
MMP2 P08253 2/20 0.46
MMP1 P03956 1/20 0.46
ACHE P22303 7/20 0.45
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9666789 0.92 EPHX1 (0.69) EPHX1
SCHEMBL320112 0.81 EPHX1 (0.85) EPHX1MMP2MMP1ACHE
SCHEMBL29255898 0.81 EPHX1 (0.39) EPHX1
SCHEMBL9666727 0.81 EPHX1 (0.57) EPHX1MMP2MMP1ACHEPOLB
SCHEMBL30786047 0.79 EPHX1 (0.90) EPHX1MMP2MMP1ACHE
SCHEMBL10400568 0.77 EPHX1 (0.70) EPHX1MMP2MMP1ACHE
SCHEMBL17133784 0.77 EPHX1 (0.95) EPHX1
SCHEMBL9323761 0.77 EPHX1 (0.82) EPHX1MMP2MMP1ACHE
SCHEMBL11519629 0.76 EPHX1 (0.52) EPHX1MMP2MMP1ACHEPOLB
SCHEMBL10558436 0.76 EPHX1 (0.68) EPHX1MMP2MMP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022721-B1 Method and composition for rejuvenating cells, tissues, organs, hair and nails ULRICH PETER C 2006-04-04 US disclosed
EP-1368029-A4 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS FARRINGTON PHARMACEUTICALS LLC (US) 2006-02-15 EP disclosed
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails ULRICH PETER C 2005-11-03 US disclosed
US-6777557-B2 Method and composition for rejuvenating cells, tissues organs, hair and nails FARRINGTON PHARMACEUTICALS, LLC 2004-08-17 US disclosed
US-6689777-B2 DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES KENNETH S. WARREN INSTITUTE 2004-02-10 US disclosed
EP-1368029-A2 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS Farrington Pharmaceuticals, LLC (US) 2003-12-10 EP disclosed
US-20030186993-A1 Anti-malarial compounds, compositions and methods KENNETH S. WARREN INSTITUTE 2003-10-02 US disclosed
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails FARRINGTON PHARMACEUTICALS, LLC 2002-12-12 US disclosed
WO-2002062301-A2 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS FARRINGTON PHARMACEUTICALS, LLC (US) 2002-08-15 WO disclosed
US-5153331-A Reacting 6-epoxyethyl-3-oxatricyclo 3.2.1.0(2,4)!octane with a thiocyanate salt and/or a thiourea NIPPON OIL COMPANY, LTD. (JP) 1992-10-06 US disclosed
EP-0452092-A2 6-Epithioethyl-3-oxatricyclo (3.2.1.02.4) octane and process for preparation thereof NIPPON OIL CO. LTD. (JP) 1991-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 EPHX1 3891/4885MMP2 1942/4885MMP1 125/4885
US-20050245512-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 EPHX1 3891/4885MMP2 1942/4885MMP1 125/4885
US-20030186993-A1 Anti-malarial compounds, compositions and methods TYR, CRYZ, RHOT2 EPHX1 2950/4885MMP2 1500/4885MMP1 4154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.